Gastrointestinal Cancer Program

胃肠道癌症计划

• 批准号: 10113610
• 负责人: Tanios Bekaii-Saab
• 金额: $ 9.94万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-04-25 至 2024-02-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10113610
• 关键词: Achievement; Address; Area; Award; Basic Science; Cancer Center Support Grant; Catchment Area; Cessation of life; Clinic; Clinical Research; Clinical Trials; Collaborations; Comprehensive Cancer Center; Development; Diagnosis; Disease; Early Diagnosis; Evaluation; Faculty; Funding; Germ-Free; Goals; Grant; Healthcare; Hepatobiliary; Incidence; Infrastructure; Investigation; Journals; Knowledge; Literature; Malignant Neoplasms; Malignant neoplasm of gastrointestinal tract; Malignant neoplasm of liver; Malignant neoplasm of pancreas; Mayo Clinic Cancer Center; Mentors; Mentorship; Mission; Mus; Outcome; Outcomes Research; Pathogenesis; Patient Care; Patient-Focused Outcomes; Patients; Peer Review; Prevention; Prognostic Marker; Publications; Research; Research Personnel; Resource Sharing; Resources; Risk; Role; Science; Scientific Advances and Accomplishments; Site; Stratification; Talents; Testing; Translational Research; United States National Institutes of Health; Work; anticancer research; base; cancer diagnosis; care outcomes; design; effective therapy; gut microbiome; improved; individualized medicine; innovation; insight; member; metabolomics; microbiome; multidisciplinary; new therapeutic target; novel; novel marker; novel strategies; predictive marker; programs; therapy outcome; tumor microbiome; tumor microenvironment

GASTROINTESTINAL CANCER PROGRAM PROJECT SUMMARY The Gastrointestinal Cancer (GI) Program of the Mayo Clinic Cancer Center (MCCC) continues to make significant contributions in the areas of basic, translational, and clinical research by using a multidisciplinary and interactive team approach. The primary objective of the GI Program is to use novel observations, mechanistic insights and research outcomes to benefit patients with GI cancers or at risk for GI malignancies, including those from our catchment area. This work is accomplished through robust intra- and interprogrammatic interactions focused on 4 Aims: 1) application of early detection approaches, 2) identification and evaluation of predictive or prognostic biomarkers, 3) role of the tumor microenvironment and microbiome in cancer development and progression, and 4) individualized therapeutic strategies. Aim 3 is a new and evolving effort that builds upon an existing base of NCI-funded investigators in these fields of research, and interacts with the Microbiome Program within the Mayo Clinic Center for Individualized Medicine to expand the existing germ-free mouse facility and a metabolomics core lab. The GI Program consists of 54 members from 17 departments. Our GI Program developed a SPORE grant in Pancreatic Cancer where major contributions and interactions continue. The GI Program also developed a Hepatobiliary (HB) SPORE proposal that received a highly competitive score with a funding decision expected in mid-2018. As a result of this score, the MCCC was awarded a CCSG supplement of $750K from the NCI with an aim to maintain the infrastructure for liver cancer research. Our NIH-funded research platform and portfolio of innovative clinical trials is expanding and benefits from interactions across the 3 MCCC sites and with other multi-institutional networks; these interactions are enhancing accrual. The GI research program is supported by total direct funding of $10.2M ($5.1M peer-reviewed, with 69% from NCI). Since 2013, Program members have contributed more than 871 publications to the literature, of which 28% represent intraprogrammatic and 31% reflect interprogrammatic collaborations; 21% are in journals with an impact factor ≥10. These publications reflect numerous scientific accomplishments and discoveries, several of which have been practice changing. Formal mentoring of junior faculty continues with an increased effort to provide pilot grant funding to our investigators.

胃肠道肿瘤治疗项目总结 马约诊所癌症中心（MCCC）的胃肠癌（GI）项目继续使 在基础，转化和临床研究领域的重大贡献，通过使用多学科 和互动的团队方法。GI计划的主要目标是使用新的观察结果， 机制见解和研究成果，使GI癌症患者或有GI恶性肿瘤风险的患者受益， 包括我们的集水区。这项工作是通过强大的内部和 方案间互动侧重于4个目标：1）应用早期发现方法，2） 预测或预后生物标志物的鉴定和评价，3）肿瘤微环境的作用， 微生物组在癌症发展和进展中的作用，以及4）个体化治疗策略。目标3是一个 新的和不断发展的努力，建立在现有的基础上，国家癌症研究所资助的调查人员在这些领域， 研究，并与马约诊所个体化医学中心的微生物组计划相互作用 扩大现有的无菌小鼠设施和代谢组学核心实验室。GI计划包括54个 来自17个部门。我们的GI计划在胰腺癌方面开发了SPORE补助金， 贡献和互动仍在继续。GI计划还制定了肝胆（HB）孢子提案 该公司获得了极具竞争力的分数，预计将于2018年年中做出融资决定。由于这个分数， 海军陆战队指挥中心从国家指挥中心获得了75万美元的CCSG补贴，目的是维护基础设施 用于肝癌研究。我们的NIH资助的研究平台和创新临床试验组合是 扩大并受益于3个MCCC站点之间的互动以及与其他多机构网络的互动; 这些互动正在加强应计制。GI研究计划由以下直接资助总额支持： 1020万美元（同行评审510万美元，其中69%来自NCI）。自2013年以来，该计划的成员贡献了更多 超过871篇文献，其中28%代表计划内，31%反映 跨学科合作; 21%的期刊影响因子≥10。这些出版物反映了 许多科学成就和发现，其中一些已经在实践中改变。正式 继续对初级教员进行指导，并加大努力向我们的调查人员提供试点赠款。